Analysts Lift Targets on Airlines, Biotech and Financials

Wall Street lifted price targets across several sectors on Thursday, with airlines, biotech and financial names drawing the most attention.

United Airlines saw the biggest consensus target move in the airline space. Analysts pushed the average target to $152.52, up from $152.48. The stock carries 22 buy ratings against just two holds and no sells, making it one of the most bullishly positioned large-caps in the sector.

Moderna received the sharpest absolute target upgrade of the session. The consensus price target rose to $130.58 from $124.72, a gain of nearly $6. The stock is notable in the index rebalance context: ORTEX's Index Rebalance Radar shows Moderna already sitting 75.4% above the MSCI World entry line, with $5.4bn of forced buying forecast if it is added at the November review.

CME Group and Northern Trust both saw target increases, reflecting broader optimism around financial sector cash generation. ORTEX alt data shows financials-sector share buybacks hit 190 million shares repurchased in Q2 2026, the highest quarterly total in 12 years, with three consecutive quarters of growth pointing to sustained capital returns.

Abbott Laboratories was the notable downgrade in targets, with the consensus slipping to $119.68 from $120.72 despite all 24 covering analysts remaining at buy.

Halliburton saw multiple changes among its analysts, though the net target moved only slightly to $43.64 from $43.32.